611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Reports Second Quarter 2026 Financial Results
Executive Appointment - Alison L. Hannah Named Chief Medical Officer
Rigel Pharmaceuticals Completes License Agreement with Arvinas and Pfizer
Material disclosure
Reports First Quarter 2026 Financial Results
Termination of License Agreement with Eli Lilly - Rigel Pharmaceuticals
Financial Results, Press Release
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership